Jean-Marc Tréluyer researcher
Tréluyer, Jean-Marc, 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Tréluyer, Jean-Marc
VIAF ID: 172660689 (Personal)
Permalink: http://viaf.org/viaf/172660689
Preferred Forms
-
100 0 _
‡a
Jean-Marc Tréluyer
‡c
researcher
-
100 1 _
‡a
Tréluyer, Jean-Marc,
‡d
19..-....
-
100 1 _
‡a
Tréluyer, Jean-Marc
Works
| Title | Sources |
|---|---|
| Adverse event of protons pump inhibitor in new born and children. |
|
| Apport d’une adaptation bayésienne précoce de la dose de vancomycine chez l’enfant |
|
| Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding |
|
| Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort |
|
| Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2 |
|
| Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy |
|
| Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. |
|
| DEFICIT HETEROZYGOTE EN PROTEINE C EN PERIODE NEONATALE : DIFFICULTES DIAGNOSTIQUES |
|
| Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach |
|
| Drug evaluation for pregnant woman in clinical trials : specificities, setbacks, and solutions. |
|
| Duoc dong hoc/ duoc luc hoc cua ganciclovir o tre em. |
|
| Early dose adjustment of vancomycin in children. |
|
| Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest: A Multicenter, Randomized Controlled Trial |
|
| Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients |
|
| Effets indésirables des inhibiteurs de la pompe à protons chez les nouveaux nés et les enfants |
|
| Etude du passage transplacentaire des antirétroviraux chez des patientes infectées par le VIH |
|
| Etude rétrospective de la tolérance du propofol chez le nouveau-né à terme ou prématuré |
|
| Évaluation du médicament chez la femme enceinte dans les études cliniques : spécificités, freins et solutions |
|
| Evaluation of different size-descriptors in obese subjects using population pharmacokinetic model : application to metformin, morphine, imatinib. |
|
| Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea |
|
| Facteurs de risque clinique et pharmacologique de lipodystrophie chez des patients infectés par le VIH : étude prospective |
|
| Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model |
|
| Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir |
|
| Intérêt de la sédation du nouveau-né en ventilation mécanique, en dehors de la periode post-opératoire |
|
| Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
|
| Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. |
|
| Lisibilité de l'information écrite destinée au patient pour un consentement éclairé à la recherche |
|
| Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial |
|
| Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children |
|
| Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? |
|
| Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women |
|
| Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics |
|
| Modulation de l'expression des transporteurs membranaires au niveau des lymphocytes et du placenta chez l'homme |
|
| Ontogenèse de la P-glycoprotéine lymphocytaire chez l'homme |
|
| Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients |
|
| An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study |
|
| Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome |
|
| Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study |
|
| Pharmacocinétique de population du nelfinavir |
|
| Pharmacocinétique / pharmacodynamie du ganciclovir chez l'enfant |
|
| Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications |
|
| Pharmacokinetics and pharmacodynamic modelling of epinephrine and norepinephrine in children. |
|
| Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children |
|
| Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old. |
|
| Pharmacological and clinical risk factors of lipodystrophy in VIH-infected patients receiving a nelfinavir-containing regimen |
|
| Pharmacological evaluation of antiretroviral treatments. |
|
| Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial |
|
| Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-centre prospective experience and clinical implications-the ERTAPRO study |
|
| Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children |
|
| Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion |
|
| Population pharmacokinetics of abacavir, stavudine and lopinavir in children. |
|
| Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis |
|
| Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy |
|
| Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates |
|
| Prédiction du passage transplacentaire in-vivo des médicaments à partir de modèles ex-vivo |
|
| Prediction of drug clearance in children |
|
| Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models |
|
| Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women |
|
| Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial |
|
| Prolongation of the QT interval in HIV patients. |
|
| Readability of written information intended for the patient in order to obtain his informed consent for clinical research. |
|
| Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation |
|
| Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease obs |
|
| Treatment and prevention of the transmission of HIV infection : pharmacokinetic analysis of emtricitabine by a population approach. |
|
| Variability factors modulating the expression and activity of efflux transporters in human lymphocytes. |
|
| Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). |
|
| VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,0 |
|
| Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol |
|
